Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 9;18(4):555.
doi: 10.3390/ph18040555.

The Emergence of Psilocybin in Psychiatry and Neuroscience

Hossein Omidian  1 , Alborz Omidian  2
Affiliations
Review

The Emergence of Psilocybin in Psychiatry and Neuroscience

Hossein Omidian et al. Pharmaceuticals (Basel). .

Abstract

Psilocybin, a naturally occurring psychedelic compound, has garnered renewed scientific interest for its potential in treating psychiatric and neurological disorders. This review systematically examines the latest research on psilocybin's pharmacokinetics, pharmacodynamics, clinical efficacy, and safety profile. Emerging evidence supports its efficacy in conditions such as major depressive disorder (MDD), treatment-resistant depression (TRD), anxiety, alcohol use disorders (AUD), and cancer-related distress. Despite promising outcomes, significant barriers remain, including methodological constraints, regulatory hurdles, and limited population diversity in clinical trials. Advances in biosynthetic production and optimized psychotherapeutic integration are necessary to ensure scalability and accessibility. Future research should focus on long-term safety, dosing precision, and neurobiological mechanisms to refine its therapeutic applications. This review provides a critical foundation for advancing evidence-based clinical integration of psilocybin.

Keywords: clinical trials; neuroplasticity; psilocybin; psychedelic therapy; psychiatric disorders.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Brown R.T., Nicholas C.R., Cozzi N.V., Gassman M.C., Cooper K.M., Muller D., Thomas C.D., Hetzel S.J., Henriquez K.M., Ribaudo A.S., et al. Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults. Clin. Pharmacokinet. 2017;56:1543–1554. doi: 10.1007/s40262-017-0540-6. - DOI - PubMed
    1. Daws R.E., Timmermann C., Giribaldi B., Sexton J.D., Wall M.B., Erritzoe D., Roseman L., Nutt D., Carhart-Harris R. Increased global integration in the brain after psilocybin therapy for depression. Nat. Med. 2022;28:844–851. doi: 10.1038/s41591-022-01744-z. - DOI - PubMed
    1. Mason N.L., Kuypers K.P.C., Muller F., Reckweg J., Tse D.H.Y., Toennes S.W., Hutten N., Jansen J.F.A., Stiers P., Feilding A., et al. Me, myself, bye: Regional alterations in glutamate and the experience of ego dissolution with psilocybin. Neuropsychopharmacology. 2020;45:2003–2011. doi: 10.1038/s41386-020-0718-8. - DOI - PMC - PubMed
    1. Fang S., Yang X., Zhang W. Efficacy and acceptability of psilocybin for primary or secondary depression: A systematic review and meta-analysis of randomized controlled trials. Front. Psychiatry. 2024;15:1359088. doi: 10.3389/fpsyt.2024.1359088. - DOI - PMC - PubMed
    1. Bogenschutz M.P., Ross S., Bhatt S., Baron T., Forcehimes A.A., Laska E., Mennenga S.E., O’Donnell K., Owens L.T., Podrebarac S., et al. Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs. Placebo in the Treatment of Adult Patients with Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2022;79:953–962. doi: 10.1001/jamapsychiatry.2022.2096. - DOI - PMC - PubMed

LinkOut - more resources